Cabozantinib Improves Survival in Advanced Hepatocellular Cancer

Cabozantinib results in significantly longer overall and progression-free survival than placebo among patients with advanced hepatocellular carcinoma, according to research in the New England Journal of Medicine. Researchers randomized 707 patients with advanced hepatocellular carcinoma in a 2-to-1 ratio to receive cabozantinib or matching placebo and found significantly longer overall survival with cabozantinib than placebo at the second planned interim analysis. The researchers found that the median overall survival was 10.2 and 8.0 months with cabozantinib and placebo, respectively.

Mon, 09 Jul 2018 BREAKING NEWS
New Rules May Constrain Docs’ Ability to Treat Chronic Pain

New laws and regulations designed to limit the use of prescription narcotics may further constrain doctors’ ability to treat patients, according to an article in Medical Economics. Physicians express concern that they cannot exercise their clinical judgement about the appropriate therapy for specific patients, and that CMS rules and CDC guidelines conflict.

Fri, 06 Jul 2018 BREAKING NEWS
Initial Outcomes No Worse for Surgical ICU Patients With CA

Surgical patients who are admitted to the intensive care unit (ICU) and have cancer do not have worse initial outcomes than those without cancer, according to research in JAMA Surgery. “Cancer is a common diagnosis among surgical ICU patients and this study suggests that initial outcomes compare favorably with those of ICU patients with other conditions,” the authors write. “Consideration that a diagnosis of cancer should not preclude admission to the ICU in patients with surgical disease is suggested.”

Fri, 29 Jun 2018 BREAKING NEWS
ADA: Closed-Loop Insulin Improves Glycemic Control

Use of an automated, closed-loop insulin delivery system results in significantly better glycemic control than conventional subcutaneous insulin therapy among patients with type 2 diabetes receiving noncritical care, according to a study published in the New England Journal of Medicine to coincide with the annual meeting of the American Diabetes Association, held in Orlando, Florida.

Fri, 29 Jun 2018 BREAKING NEWS
Insulin Glargine 300 Safe, Effective in Seniors With T2DM

For older adults, insulin glargine 300 units/mL (Gla-300) is safe and as effective as Gla-100, with a similarly low or lower risk of symptomatic hypoglycemia, research in Diabetes Care suggests. From baseline to week 26, the reductions in HbA1c were comparable for Gla-300 and Gla-100 in the overall population and for participants aged ≥75 years. “Gla-300 demonstrated good efficacy and safety in older people with type 2 diabetes, particularly in those of advanced age (≥75 years),” the authors write.

Wed, 27 Jun 2018 BREAKING NEWS
In Cancer Patients, PTSD May Increase Symptom Burden

Post-traumatic stress disorder (PTSD) symptoms among hospitalized patients with cancer are associated with a greater psychological and physical symptom burden as well as a decreased risk of hospital readmissions, according to a study published in Cancer. The researchers found that 13.3% of patients screened positive for PTSD symptoms. The 90-day hospital readmission rate was 38.9%. “Interventions to address patients’ PTSD symptoms are needed and should account for their physical and psychological symptom burden,” write the authors.

Mon, 25 Jun 2018 BREAKING NEWS